4.96
-0.13
(-2.55%)
After Hours: 4.96
0.00
(0.00%)
Jun 18, 4:31PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 4.95 - 5.12 |
| 52 week | 3.16 - 6.56 |
| Open | 5.10 |
| Vol / Avg. | 1.17M/1.67M |
| Mkt cap | 579.21M |
| P/E | - |
| Div/yield | - |
| EPS | -0.48 |
| Shares | 116.78M |
| Beta | 1.60 |
| Inst. own | 79% |
Events
Aug 12, 2013
Q4 2013 Array BioPharma Inc. Earnings Release
Jun 19, 2013
Array BioPharma Inc. at Wells Fargo Health Care Conference
- 9:15AM EDT -
Jun 5, 2013
Array BioPharma Inc. at Jefferies Global Healthcare Conference -
May 30, 2013
Array BioPharma Inc Conference Call to discuss its Collaboration with Oncothyreon to Develop and Commercialize anti-HER2 Compound ARRY-380 -
May 21, 2013
Array BioPharma Inc. at UBS Global Healthcare Conference -
May 17, 2013
Array BioPharma Inc. at Bank of America Merrill Lynch Health Care Conference -
May 7, 2013
Q3 2013 Array BioPharma Inc. Earnings Conference Call -
Apr 29, 2013
Q3 2013 Array BioPharma Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -216.92% | -27.70% |
| Operating margin | -188.60% | -14.08% |
| EBITD margin | - | -6.99% |
| Return on average assets | -73.46% | -23.89% |
| Return on average equity | - | - |
| Employees | 250 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company�s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
Officers and directors
| Kyle A. Lefkoff | Independent Chairman of the Board | |
| Kevin Koch Ph.D. | President, Chief Scientific Officer | |
| Ron Squarer | Chief Executive Officer, Director | |
| R. Michael Carruthers | Chief Financial Officer | |
| David L. Snitman Ph.D. | Chief Operating Officer, Vice President - Business Development | |
| John R. Moore | Vice President, General Counsel, Secretary | |
| Michael N. Needle M.D. | Chief Medical Officer | |
| John L. Zabriskie Ph.D. | Lead Independent Director | |
| Gwendolyn A Fyfe MD | Independent Director | |
| John A. Orwin | Independent Director |